# US 5,702,697 A · Treatment for biological damage using a colony stimulating factor and a biological modifier > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,702,697 A - Document ID: US5702697A - Status: Granted - Kind: A - Application number: 08/457,629 - Filed: 1995-06-01 - Granted: 1997-12-30 - Earliest claimed: 1986-11-21 - Assignees: Chiron Corporation - Inventors: Robert Zimmerman; Benedict J. Marafino, Jr. - Web page: https://patentgrep.com/patent/US5702697A ## CPC - A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta} - A61K 38/2013: {IL-2} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Damage to cells, tissue and other body parts in a mammalian host may be treated by using a colony stimulating factor in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy. ## Claims ### Claim 1 A method for the therapeutic or prophylactic treatment of biological damage to a mammalian host, said damage caused by free radical generation, which method comprises administering to the host in need of such treatment therapeutically effective amounts of a colony stimulating factor from a mammalian species and at least one biological modifier selected from the group consisting of a free radical scavenger and a metabolic inhibitor. ### Claim 2 (depends on 1) The method of claim 1 wherein the colony stimulating factor and the biological modifier are administered separately to the host, and the biological modifier is administered first. ### Claim 3 (depends on 1) The method of claim 1 wherein the biological modifier is selected from the group consisting of uric acid, buthionine sulphoximine, vitamin E, vitamin C, N-acetyl cysteine, a retinoid, gluathione, metronidazole, aspirin, indomethacin, ibuprofen, nordihydroguaiaretic acid, cis-8,11,14-eicosatrien-5-ynoic acid, synthetic prostaglandins, synthetic leukotrienes, and combinations thereof. ### Claim 4 (depends on 1) The method of claim 1 wherein said biological modifier is administered to the host at least once prior to administration to the host of said colony stimulating factor. ### Claim 5 (depends on 1) The method of claim 1 wherein the colony stimulating factor is selected from the group consisting of colony stimulating factor-1 (CSF-1) and granulocyte-macrophage colony stimulating factor (CSF-GM). ### Claim 6 (depends on 5) The method of claim 5 wherein the colony stimulating factor is CSF-1. ### Claim 7 (depends on 1) The method of claim 1 wherein the host is human and the biological damage results from a cause selected from the group consisting of infection, high oxygen tension, radiation therapy, and chemotherapy. ### Claim 8 (depends on 1) The method of claim 1 wherein the biological modifier is a free radical scavenger. ### Claim 9 (depends on 8) The method of claim 8 wherein the biological damage caused by free radical generation is caused by free radicals produced as a mechanism for killing cells. ### Claim 10 (depends on 1) The method of claim 1 wherein the biological modifier is a metabolic inhibitor. ### Claim 11 A composition comprising therapeutically effective amounts of a colony stimulating factor from a mammalian species and of a biological modifier selected from the group consisting of a free radical scavenger and a metabolic inhibitor. ### Claim 12 (depends on 11) The composition of claim 11 further comprising a pharmaceutically acceptable carrier medium. ### Claim 13 (depends on 11) The composition of claim 11 wherein the colony stimulating factor is selected from the group consisting of colony stimulating factor-1 (CSF-1) and granulocyte-macrophage colony stimulating factor (CSF-GM). ### Claim 14 (depends on 13) The composition of claim 13 wherein the colony stimulating factor is colony stimulating Factor-1. ### Claim 15 (depends on 13) The composition of claim 13 wherein the colony stimulating factor is CSF-GM. ### Claim 16 (depends on 11) The composition of claim 11 wherein the biological modifier is selected form the group consisting of uric acid, buthionine sulphoximine, vitamin E, vitamin C, N-acetyl cysteine, a retinoid, glutathione, metronidazole, aspirin, indomethacin, ibuprofen, nordihydroguaiaretic acid, cis-8,11,14-eicosatrien-5-ynoic acid, synthetic prostaglandins, synthetic leukotrienes, and combinations thereof. ### Claim 17 (depends on 11) The composition of claim 11 wherein the biological modifier is a free radical scavenger. ### Claim 18 (depends on 11) The composition of claim 11 wherein the biological modifier is a metabolic inhibitor. ### Claim 19 A method for treating biological damage in a host in need of such treatment, wherein said damage is caused by free radical generation, which method comprises administering to the host a therapeutically effective amount of a biological modifier in a first pharmaceutically acceptable carrier, said biological modifier selected from the group consisting of a free radical scavenger and a metabolic inhibitor, and administering to the host a therapeutically effective amount of a colony stimulating factor in a second pharmaceutically acceptable carrier. ### Claim 20 (depends on 19) The method of claim 19 wherein the biological damage is cancer. ### Claim 21 (depends on 20) The method of claim 20 wherein the colony stimulating factor is selected from the group consisting of colony stimulating factor-1 (CSF-1) and granulocyte-macrophage colony stimulating factor (CSF-GM). ### Claim 22 (depends on 20) The method of claim 20 wherein the biological modifier is a free radical scavenger. ### Claim 23 (depends on 20) The method of claim 20 wherein the biological modifier is a metabolic inhibitor. ### Claim 24 A unit dose comprising a first composition having a therapeutically effective amount of a colony stimulating factor from a mammalian species, and further comprising a second composition having a therapeutically effective amount of a biological modifier selected from the group consisting of a free radical scavenger and a metabolic inhibitor. ### Claim 25 (depends on 24) The unit dose of claim 24 wherein said first composition and said second composition are cooperatively combined but not in admixture. ### Claim 26 (depends on 25) The unit dose of claim 25 wherein the colony stimulating factor is selected from the group consisting of colony stimulating factor-1 (CSF-1) and granulocyte-macrophage colony stimulating factor (CSF-GM). ### Claim 27 (depends on 26) The unit dose of claim 26 wherein the biological modifier is a free radical scavenger. ### Claim 28 (depends on 27) The unit dose of claim 27 wherein the free radical scavenger is selected from the group consisting of uric acid, buthionine sulphoximine, N-acetyl cysteine, and vitamin C. ### Claim 29 A kit comprising a therapeutically effective amount of a colony stimulating factor from a mammalian species in association with a therapeutically effective amount of a biological modifier selected from the group consisting of a free radical scavenger and a metabolic inhibitor, said kit facilitating separate administration to a host of said therapeutically effective amount of a colony stimulating factor and said therapeutically effective amount of a biological modifier. ### Claim 30 (depends on 29) The kit of claim 29 wherein the colony stimulating factor is selected from the group consisting of colony stimulating factor-1 (CSF-1) and granulocyte-macrophage colony stimulating factor (CSF-GM). ### Claim 31 (depends on 30) The kit of claim 30 wherein the biological modifier is a free radical scavenger. ### Claim 32 (depends on 31) The kit of claim 31 wherein the free radical scavenger is selected from the group consisting of uric acid, buthionine sulphoximine, N-acetyl cysteine, and vitamin C.